These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 8376957)
1. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957 [TBL] [Abstract][Full Text] [Related]
2. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316 [TBL] [Abstract][Full Text] [Related]
3. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Luke W; Coulibaly C; Dittmer U; Voss G; Oesterle R; Makoschey B; Sauermann U; Jurkiewicz E; Stahl-Henning C; Petry H; Hunsmann G Virology; 1996 Feb; 216(2):444-50. PubMed ID: 8607276 [TBL] [Abstract][Full Text] [Related]
4. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. Giavedoni LD; Planelles V; Haigwood NL; Ahmad S; Kluge JD; Marthas ML; Gardner MB; Luciw PA; Yilma TD J Virol; 1993 Jan; 67(1):577-83. PubMed ID: 8416384 [TBL] [Abstract][Full Text] [Related]
5. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. Torres JV; Malley A; Banapour B; Anderson DE; Axthelm MK; Gardner MB; Benjamini E AIDS Res Hum Retroviruses; 1993 May; 9(5):423-30. PubMed ID: 7686386 [TBL] [Abstract][Full Text] [Related]
6. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. Israel ZR; Edmonson PF; Maul DH; O'Neil SP; Mossman SP; Thiriart C; Fabry L; Van Opstal O; Bruck C; Bex F J Virol; 1994 Mar; 68(3):1843-53. PubMed ID: 8107246 [TBL] [Abstract][Full Text] [Related]
7. Comparison of humoral immunity and induction of proliferating T lymphocytes in vaccinia virus-infected rabbits and rhesus macaques. Schäffner JW; Dittmer U; Otteken A; Coulibaly C; Bodemer W; Voss G; Hunsmann G Am J Vet Res; 1994 Sep; 55(9):1250-5. PubMed ID: 7802392 [TBL] [Abstract][Full Text] [Related]
8. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159 [TBL] [Abstract][Full Text] [Related]
9. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques. Meyer D; Anderson DE; Gardner MB; Torres JV AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375 [TBL] [Abstract][Full Text] [Related]
10. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy. Mills KH; Page M; Kitchin P; Chan L; Jones W; Silvera P; Corcoran T; Flanagan B; Ling C; Thiriart C J Med Primatol; 1993; 22(2-3):104-9. PubMed ID: 8411102 [TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity. Mills KH; Barnard AL; Williams M; Page M; Ling C; Stott EJ; Silvera P; Taffs F; Kingsman AS; Adams SE J Immunol; 1991 Nov; 147(10):3560-7. PubMed ID: 1719081 [TBL] [Abstract][Full Text] [Related]
12. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins. Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322 [TBL] [Abstract][Full Text] [Related]
14. Emergence of antigenic variants of simian immunodeficiency virus (SIVmac) in a seronegative macaque after SIVmac239 infection. Chuang LF; Blackbourn DJ; Chuang AJ; Killam KF; Liu X; Li Y; Kung HF; Chuang RY Cell Mol Biol Res; 1994; 40(7-8):661-9. PubMed ID: 7787884 [TBL] [Abstract][Full Text] [Related]
15. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques. Torres JV; Anderson DE; Malley A; Banapour B; Axthelm MK; Benjamini E; Gardner MB J Med Primatol; 1993; 22(2-3):129-37. PubMed ID: 7692056 [TBL] [Abstract][Full Text] [Related]
16. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. Jurkiewicz E; Hunsmann G; Schäffner J; Nisslein T; Lüke W; Petry H J Virol; 1997 Dec; 71(12):9475-81. PubMed ID: 9371609 [TBL] [Abstract][Full Text] [Related]
17. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. Lehner T; Brookes R; Panagiotidi C; Tao L; Klavinskis LS; Walker J; Walker P; Ward R; Hussain L; Gearing JH Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8638-42. PubMed ID: 7690967 [TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918 [TBL] [Abstract][Full Text] [Related]
19. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. Stahl-Hennig C; Voss G; Dittmer U; Coulibaly C; Petry H; Makoschey B; Cranage MP; Aubertin AM; Lüke W; Hunsmann G AIDS; 1993 Jun; 7(6):787-95. PubMed ID: 8363756 [TBL] [Abstract][Full Text] [Related]
20. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Nilsson C; Mäkitalo B; Berglund P; Bex F; Liljeström P; Sutter G; Erfle V; ten Haaft P; Heeney J; Biberfeld G; Thorstensson R Vaccine; 2001 May; 19(25-26):3526-36. PubMed ID: 11348720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]